academic article

• Ofatumumab versus Teriflunomide in Multiple Sclerosis..  The New England journal of medicine.  383:546-557. 2020
• Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study..  Lancet.  391:1263-1273. 2018
• Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis..  The New England journal of medicine.  376:221-234. 2017
• Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis..  The New England journal of medicine.  376:209-220. 2017
• 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study..  Lancet neurology.  8:889-897. 2009